Robins Kaplan Named Plaintiffs Firm of the Year for Antitrust by The National Law Journal
July 18, 2023
Robins Kaplan LLP is thrilled to announce that it has been named the inaugural Plaintiffs Firm of the Year for Antitrust by The National Law Journal in its 2023 Elite Trial Lawyers Awards. The firm’s Antitrust and Trade Regulation Group is recognized for its outstanding contributions to plaintiffs-side legal work and professional excellence.
“We are grateful our clients choose us to represent them in some of the most precedential antitrust cases in the country. It is an honor to work in the antitrust field and we are delighted to be recognized for this work in The National Law Journal this year,” said Kellie Lerner, co-chair of the Antitrust and Trade Regulation Group.
“It is an honor to be recognized by The National Law Journal for our many achievements in antitrust law over the past year. From our historic Interchange result to securing final settlements in the Disposable Contact Lens litigation, our antitrust group is deeply committed to seeking justice on behalf of plaintiffs,” added Stacey Slaughter, co-chair of the Antitrust and Trade Regulation Group.
The firm’s Antitrust and Trade Regulation Group’s recent successes include:
- Obtained decision from the United States Court of Appeals for the Second Circuit unanimously upholding the District Court’s order approving the $5.6 billion settlement on behalf of U.S. merchants in the In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation. It is the largest settlement of a private antitrust action in the 130-year history of the Sherman Act.
- Obtained settlements totaling $75 million with the final two defendants in the expansive In re Disposable Contact Lens Antitrust Litigation, bringing total settlements on behalf of U.S. contact lens purchasers to more than $118 million in the long-running antitrust class action against the four dominant manufacturers and the largest nationwide distributor of contact lenses.
- Obtained a settlement worth up to $28 million on behalf of a class of third party payors who alleged that Martin Shkreli and his former companies illegally monopolized the market for Daraprim—a once-affordable, life-saving drug that increased in price by more than 4,000 percent under Shkreli’s leadership.
View the full list of 2023 Elite Trial Lawyers winners here.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.